At what enterprise value was DOCTOLIB acquired in 2022?

During the acquisition of DOCTOLIB by BPIFRANCE / EURAZEO in 2022, the company was valued at an estimated revenue multiple of Above 20x. The transaction's Enterprise Value is estimated to be in the range of 3b - 100b EUR. By registering for free, you get access to complete and exact transaction details including enterprise value, revenue, and EBITDA. Additionally, our database shows that the TMT (Tech, Media, Telecom) industry currently tracks an average EBITDA multiple of 14.4x, providing a valuable benchmark for this transaction.

What was the EV/EBITDA of DOCTOLIB when it was acquired by BPIFRANCE / EURAZEO?

The exact EV/EBITDA multiple for DOCTOLIB is available on mynth capital. For comparison, the TMT (Tech, Media, Telecom) sector currently shows an average EBITDA multiple of 14.4x. Join our community for free to access full valuation data and industry trends.

When was DOCTOLIB acquired by BPIFRANCE / EURAZEO?

DOCTOLIB was acquired by BPIFRANCE / EURAZEO in 2022.

What was the revenue of DOCTOLIB at the time of the deal?

The revenue of DOCTOLIB at the time of the deal is estimated to be in the range of 150M - 250M EUR. Register for free to access the full transaction report and exact valuation multiples.

What is Enterprise Value (EV)?

Enterprise Value (EV) is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. EV includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.

What is the EV/EBITDA multiple and why is it used?

The EV/EBITDA multiple is a financial ratio that compares a company's Enterprise Value (EV) to its Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA). It is widely used in M&A and valuation because it allows for comparisons between companies with different capital structures and provides a clear view of operational profitability.

How is the data for the DOCTOLIB acquisition sourced and is it reliable?

Mynth data is contributed by a professional community of M&A and Private Equity experts. Each transaction, including the DOCTOLIB deal, is systematically cross-verified by our team using private deal documents and official sources. You can also find the official press release for this transaction here: https://capitalfinance.lesechos.fr/deals/capital-risque/doctolib-se-valorise-58-md-apres-sa-nouvelle-levee-de-500-m-1393922

← DATABASE

Home Database TMT (Tech, Media, Telecom)DOCTOLIB

03/2022

DOCTOLIB acquired by BPIFRANCE & EURAZEO

FRANCE Software / Industry-Specific Software / Healthcare EV 3b - 100b EUR

Context

This transaction represents a significant Series G financing round for Doctolib, a leading European e-health platform. The capital infusion solidified the company's position as the most valuable technology startup in France at the time, underscoring strong investor confidence in its business model and growth trajectory in the digital health sector. The primary rationale for the fundraising was to accelerate the company's strategic initiatives across Europe. The proceeds are earmarked for several key areas: first, to deepen market penetration in its existing geographies of France, Germany, and Italy by significantly expanding its commercial teams to onboard a larger percentage of healthcare professionals. Second, the funding is intended to fuel substantial investment in product development and innovation. The company aims to evolve beyond its core appointment-booking service by launching new software solutions, such as a secure messaging service for caregivers and advanced administrative and medical software for practices. This strategic move aims to create a more integrated and indispensable ecosystem for healthcare providers. The transaction was led by prominent French investors, reflecting a desire to maintain a strong domestic influence in the shareholding structure of a company considered a national technology champion with a critical role in the country's healthcare infrastructure.

DOCTOLIB, which reported an EBITDA margin of LOGIN in 2022, is valued in this transaction at an EV/EBITDA multiple of LOGIN, a level to compare with the average currently observed in the TMT (Tech, Media, Telecom) sector (14.4x).

Note that this data is based on contribution from our growing community, composed of M&A and Private Equity professionals, and has been verified by our team to ensure its accuracy.

-> Deep-dive in TMT (Tech, Media, Telecom) market trends

Target

Doctolib is a European digital health and artificial intelligence technology company headquartered in France. Founded initially as an online platform for booking medical appointments, the company has since evolved into a comprehensive provider of software-as-a-service (SaaS) solutions for the healthcare industry. Its integrated suite of tools is designed to support healthcare professionals and facilities by streamlining administrative and clinical workflows. Key offerings include practice management software, electronic patient records, secure digital communication tools, billing and claims processing, and telehealth services. The company also develops AI-powered assistants to help with tasks like clinical documentation and call management, aiming to reduce the administrative load on caregivers. Doctolib operates across several major European markets, including France, Germany, Italy, and the Netherlands, tailoring its products to comply with the specific regulatory frameworks and clinical practices of each country's healthcare system. By 2025, the company served a network of hundreds of thousands of healthcare professionals and had achieved profitability.

Ent. Value

Equity Value

Multiples

EV / Revenue

EV / EBITDA

EV / EBIT

Historical Financials (EUR)

Year

Rev

EBITDA

EBIT

2022

2021

Other operations with DOCTOLIB

List of similar M&A transactions (Date, Acquirer, Target, Country, Sector, Deal Context)
Date	Acquirer	Target	Country	Sector	Deal Context
05/2026	DOCTOLIB	MEDICUS	United Kingdom	Software	Doctolib executed a strategic acquisition of Medicus, a UK-based developer of clinical software for the National Health Service (NHS), marking its official entry into the United Kingdom. This transaction represents a key milestone in Doctolib's European expansion, adding the UK as its fifth operational market alongside France, Germany, Italy, and the Netherlands
04/2026	ATHOS CONSORTIUM / A.P. MOLLER HOLDING	DOCTOLIB	France	Software	This transaction was a significant secondary market operation, providing liquidity to early stakeholders rather than raising new capital for the company. The deal was structured to allow historical business angels and long-term employees to sell a portion of their vested shares, enabling them to realize a return on their investment and involvement since the company's inception

REFERENCES

Valuation range: EV 3b - 100b EUR

Revenue range: 150M - 250M EUR

Note: This page provides detailed data on a private equity M&A transaction. Detailed and exact financial metrics for the acquisition of DOCTOLIB by BPIFRANCE / EURAZEO are reserved for mynth community members. Register for free to unlock full data.

Authors: verified mynth contributor (mynth data is contributed by M&A / PE professionals and systematically cross-verified with private deal documents and official press releases).

Target: doctolib

Acquirer: eurazeo / bpifrance